Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 36 of 65 · 3115 articles
The study links NEAT1, a long noncoding RNA, to neutrophil-driven mucosal inflammation in ulcerative colitis and suggests NEAT1 affects neutrophil activity via glycolysis. That points to a new molecular pathway that...
A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
Anemia is a common complication of IBD and can worsen quality of life. This study suggests endotoxins leaking from an inflamed gut may drive anemia through TLR4 on tissue-resident macrophages, highlighting a possible new...
Smoking and similar nicotine-product use after Crohn's surgery appears linked to higher rates of endoscopic recurrence, which may affect postoperative monitoring and secondary-prevention strategies. Patients using HNBT...
This study highlights a potential new molecular player (ABLIM3) involved in colitis-related epithelial and cytoskeletal changes. Understanding such mechanisms could eventually point to new targets for therapies or...
The review shows psychotherapies can improve quality of life and reduce anxiety and depression in people with IBD, outcomes that matter for daily functioning even when intestinal symptoms may not change.
This work suggests a new way Crohn’s disease might begin: a weaker early immune response (linked to NOD2 gene defects) allows small intestinal infections to persist and later trigger the inflammation that causes...
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
Timing of therapies and daily behaviors may affect drug metabolism, immune activity, and symptom patterns in IBD. Considering when treatments are given could potentially improve response, reduce toxicity, and help...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
Accurate measurement of physical activity matters because it’s linked to symptoms, fitness, and overall health.
The study describes a new ultrasound-activated nanozyme that reduced intestinal inflammation and promoted mucosal repair in preclinical IBD models by scavenging ROS and modulating the gut microbiota—an approach that...
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.
This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.
Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...
Cure8 found this source from journals.lww.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
The study suggests a targeted microbiome-based drug (sialidase inhibitor) may protect the mucus barrier and improve symptoms in ulcerative colitis without the broad disruption caused by antibiotics, which could be...
Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk...
People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
This study suggests a plant extract might boost ketone-body levels and reduce colitis-like inflammation in a mouse model — a concept that could inform future dietary or therapeutic research for ulcerative colitis but is...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
This preclinical study suggests a fox-derived Lactiplantibacillus plantarum strain can reduce inflammation and improve intestinal barrier markers in cell and mouse models of colitis, which could inform future...
The study links specific foods and combined dietary patterns with higher or lower odds of ulcerative colitis, which could inform patient conversations about diet and priorities for future research.
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...
Synthetic, severity-controlled endoscopic images could help researchers train and test IBD imaging algorithms and augment scarce labeled datasets, which may accelerate development of tools that interpret endoscopy for...
The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...
Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
A new oral investigational therapy (TAK-279) is being tested in a randomized phase 2 trial for moderate–severe ulcerative colitis. Trial results could influence future treatment options if the drug proves safe and...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
